Results of a phase I/II trial adding carmustine (300mg/m2) to melphalan (200mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation

R. L. Comenzo, H. Hassoun, T. Kewalramani, V. Klimek, M. Dhodapkar, L. Reich, J. Teruya-Feldstein, M. Fleisher, D. Filippa, S. D. Nimer

Research output: Contribution to journalArticle

8 Scopus citations

Fingerprint Dive into the research topics of 'Results of a phase I/II trial adding carmustine (300mg/m<sup>2</sup>) to melphalan (200mg/m<sup>2</sup>) in multiple myeloma patients undergoing autologous stem cell transplantation'. Together they form a unique fingerprint.

Medicine & Life Sciences